Oblenio Bio Secures $62M to Advance Autoimmune Immune Reset Therapy LBL-051 into Clinic
July 2, 2026, 9:37 am
Oblenio Bio raised $62 million in Series B funding. Pfizer Ventures led the round, with Deep Track Capital and GV joining. Funds will advance LBL-051, a tri-specific T-cell engager, into clinical development. LBL-051 targets refractory autoimmune diseases. It aims for a broad immune system reset. Preclinical data demonstrated safe, complete depletion of B cells and plasma cells. This leads to the emergence of immature, non-memory B cells. No cytokine release syndrome was observed. The therapy seeks long-term, drug-free remission. A first-in-human study begins this year. New board members joined, bolstering leadership. This funding propels a transformative approach to autoimmune disease.
Oblenio Bio stands at a pivotal juncture. The Cambridge, MA-based biotechnology firm recently completed an oversubscribed $62 million Series B financing. This significant capital influx fuels a crucial mission. It propels LBL-051, Oblenio's lead autoimmune disease program, toward clinical trials.
Pfizer Ventures spearheaded the funding round. New strategic investors Deep Track Capital and GV joined the syndicate. Aditum Bio, a founding investor from Series A, also participated. This diverse investor base validates Oblenio's innovative approach. It underscores confidence in LBL-051's potential.
LBL-051 represents a novel therapeutic strategy. It is a tri-specific T-cell engager. This design aims for a broad immune system reset. The target population includes patients with refractory autoimmune diseases. These individuals often lack effective, long-term treatment options. Oblenio seeks to change this landscape.
The therapy operates by uniting three validated targets: BCMA, CD19, and CD3. This multi-pronged attack is engineered for precision. Its primary goal is the safe and complete depletion of B cells and plasma cells. These cells play critical roles in autoimmune pathology. Eliminating them effectively could offer profound relief.
A key objective of LBL-051 is long-term, drug-free remission. This outcome remains the ultimate aspiration for many autoimmune patients. Current treatments often manage symptoms. They rarely offer sustained freedom from disease activity or medication. Oblenio's approach could redefine treatment paradigms.
Preclinical data recently highlighted LBL-051's promise. The findings were presented at the 2026 European Congress of Rheumatology. They showcased the therapy's ability to achieve a deep and durable immune reset. These results are encouraging for future clinical success.
Studies in non-human primates demonstrated compelling efficacy. Step-up dosing schedules were employed. These led to complete depletion of both peripheral and tissue B cells. Plasma cell populations also vanished. This comprehensive clearance is vital for effective immune reset.
Following depletion, a notable recovery pattern emerged. Immature, non-memory B cells reappeared in the blood. This specific repopulation mirrors observations in human patients. These patients have achieved lasting drug-free remissions. The preclinical data thus aligns with desired clinical outcomes.
Safety is paramount in any new therapy. LBL-051 demonstrated an excellent safety profile in preclinical models. Importantly, it did not induce cytokine release syndrome. This was true even at high exposure levels. Cytokine release syndrome is a common and serious side effect of many T-cell engagers. Avoiding this offers a significant advantage.
The therapy also showed dose-dependent decreases in peripheral blood immunoglobulins. This finding directly correlates with plasma cell depletion. It further confirms LBL-051's targeted mechanism of action. The data collectively supports a robust clinical development plan.
The Series B proceeds will drive LBL-051 into its initial clinical development phase. This includes a crucial milestone: the initiation of a first-in-human proof-of-concept study. This study is slated for launch this year. It represents a critical step towards patient access.
The company leadership reinforces its commitment. Samantha Truex leads Oblenio Bio as CEO. The team remains singularly focused on establishing LBL-051's broad potential. They aim to validate this approach across various autoimmune indications.
The financing also brought new expertise to Oblenio's Board of Directors. Irena Melnikova, Ph.D., Partner at Pfizer Ventures, joined the board. Rebecca Luse, Managing Director at Deep Track Capital, also assumed a board position. They join existing board members Samantha Truex, Joe Jimenez, and Josh Gertsman.
Xiaoqiang Kang, Founder, Chairman, and CEO of Leads Biolabs, will serve as a Board Observer. This appointment highlights a strategic partnership. Oblenio holds an exclusive option from Leads Biolabs. This option grants a global license. It covers LBL-051's development, manufacturing, and commercialization worldwide.
This collaboration expands Oblenio's reach. It secures global rights for a potentially transformative therapy. The partnership underscores the international scope of LBL-051's promise. It signifies a collective effort to address unmet patient needs globally.
The field of autoimmune disease demands innovation. Millions suffer from debilitating conditions. Existing therapies often fall short. LBL-051 offers new hope. Its precise mechanism and preclinical safety profile distinguish it. The goal is not just management but durable remission.
This $62 million funding round marks a pivotal moment for Oblenio Bio. It provides the necessary capital and strategic backing. The company is now poised to translate groundbreaking science into patient benefit. The journey toward a broad immune reset begins. The potential for life-changing impact is immense.
Oblenio Bio stands at a pivotal juncture. The Cambridge, MA-based biotechnology firm recently completed an oversubscribed $62 million Series B financing. This significant capital influx fuels a crucial mission. It propels LBL-051, Oblenio's lead autoimmune disease program, toward clinical trials.
Pfizer Ventures spearheaded the funding round. New strategic investors Deep Track Capital and GV joined the syndicate. Aditum Bio, a founding investor from Series A, also participated. This diverse investor base validates Oblenio's innovative approach. It underscores confidence in LBL-051's potential.
LBL-051 represents a novel therapeutic strategy. It is a tri-specific T-cell engager. This design aims for a broad immune system reset. The target population includes patients with refractory autoimmune diseases. These individuals often lack effective, long-term treatment options. Oblenio seeks to change this landscape.
The therapy operates by uniting three validated targets: BCMA, CD19, and CD3. This multi-pronged attack is engineered for precision. Its primary goal is the safe and complete depletion of B cells and plasma cells. These cells play critical roles in autoimmune pathology. Eliminating them effectively could offer profound relief.
A key objective of LBL-051 is long-term, drug-free remission. This outcome remains the ultimate aspiration for many autoimmune patients. Current treatments often manage symptoms. They rarely offer sustained freedom from disease activity or medication. Oblenio's approach could redefine treatment paradigms.
Preclinical data recently highlighted LBL-051's promise. The findings were presented at the 2026 European Congress of Rheumatology. They showcased the therapy's ability to achieve a deep and durable immune reset. These results are encouraging for future clinical success.
Studies in non-human primates demonstrated compelling efficacy. Step-up dosing schedules were employed. These led to complete depletion of both peripheral and tissue B cells. Plasma cell populations also vanished. This comprehensive clearance is vital for effective immune reset.
Following depletion, a notable recovery pattern emerged. Immature, non-memory B cells reappeared in the blood. This specific repopulation mirrors observations in human patients. These patients have achieved lasting drug-free remissions. The preclinical data thus aligns with desired clinical outcomes.
Safety is paramount in any new therapy. LBL-051 demonstrated an excellent safety profile in preclinical models. Importantly, it did not induce cytokine release syndrome. This was true even at high exposure levels. Cytokine release syndrome is a common and serious side effect of many T-cell engagers. Avoiding this offers a significant advantage.
The therapy also showed dose-dependent decreases in peripheral blood immunoglobulins. This finding directly correlates with plasma cell depletion. It further confirms LBL-051's targeted mechanism of action. The data collectively supports a robust clinical development plan.
The Series B proceeds will drive LBL-051 into its initial clinical development phase. This includes a crucial milestone: the initiation of a first-in-human proof-of-concept study. This study is slated for launch this year. It represents a critical step towards patient access.
The company leadership reinforces its commitment. Samantha Truex leads Oblenio Bio as CEO. The team remains singularly focused on establishing LBL-051's broad potential. They aim to validate this approach across various autoimmune indications.
The financing also brought new expertise to Oblenio's Board of Directors. Irena Melnikova, Ph.D., Partner at Pfizer Ventures, joined the board. Rebecca Luse, Managing Director at Deep Track Capital, also assumed a board position. They join existing board members Samantha Truex, Joe Jimenez, and Josh Gertsman.
Xiaoqiang Kang, Founder, Chairman, and CEO of Leads Biolabs, will serve as a Board Observer. This appointment highlights a strategic partnership. Oblenio holds an exclusive option from Leads Biolabs. This option grants a global license. It covers LBL-051's development, manufacturing, and commercialization worldwide.
This collaboration expands Oblenio's reach. It secures global rights for a potentially transformative therapy. The partnership underscores the international scope of LBL-051's promise. It signifies a collective effort to address unmet patient needs globally.
The field of autoimmune disease demands innovation. Millions suffer from debilitating conditions. Existing therapies often fall short. LBL-051 offers new hope. Its precise mechanism and preclinical safety profile distinguish it. The goal is not just management but durable remission.
This $62 million funding round marks a pivotal moment for Oblenio Bio. It provides the necessary capital and strategic backing. The company is now poised to translate groundbreaking science into patient benefit. The journey toward a broad immune reset begins. The potential for life-changing impact is immense.